Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Hyg Environ Health ; 222(7): 1038-1046, 2019 08.
Article in English | MEDLINE | ID: mdl-31300293

ABSTRACT

METHODS: We conducted a study of per- and polyfluoroalkyl substance biomarkers, including PFOA, in girls from Greater Cincinnati (CIN, N = 353) and the San Francisco Bay Area (SFBA, N = 351). PFOA was measured in the baseline serum sample collected in 2004-2007 of 704 girls at age 6-8 years. Mixed effects models were used to derive the effect of PFOA on BMI, waist-to-height and waist-to-hip ratios over increasing age in this longitudinal cohort. RESULTS: Median PFOA serum concentrations were 7.3 (CIN) and 5.8 (SFBA) ng/mL, above the U.S. population median for children 12-19 years in 2005-2006 (3.8 ng/mL). Log-transformed serum PFOA had a strong inverse association with BMIz in the CIN girls (p = 0.0002) and the combined two-site data (p = 0.0008); the joint inverse effect of PFOA and Age*PFOA weakened at age at 10-11 years. However, in the SFBA group alone, the relationship was not significant (p = 0.1641) with no evidence of changing effect with age. The effect of PFOA on waist:height ratio was similar to BMIz at both sites, but we did not find a significant effect of PFOA on waist:hip ratio in either the CIN or SFBA girls. CONCLUSIONS: PFOA is associated with decreased BMI and waist:height ratio in young girls, but the strength of the relationship decreases with age. Site heterogeneity may be due to greater early life exposure in Cincinnati. DISCLAIMER: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.


Subject(s)
Body Mass Index , Caprylates/blood , Environmental Pollutants/blood , Fluorocarbons/blood , Waist-Height Ratio , Adolescent , Age Factors , Biological Monitoring , California , Child , Cities , Female , Humans , Ohio , Waist-Hip Ratio
2.
Am J Vet Res ; 61(6): 710-3, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10850850

ABSTRACT

OBJECTIVE: To determine the efficacy of difloxacin, a novel fluoroquinolone antibiotic, in calves experimentally infected with Mannheimia haemolytica (formerly Pasteurella haemolytica). ANIMALS: Seventy-two 3-month-old Holstein calves. PROCEDURES: Calves were inoculated with M haemolytica intratracheally; after they developed clinical signs of pneumonic pasteurellosis, they were randomly assigned to 1 of 6 groups (n = 12/group). Calves in each group were treated with 10% difloxacin (2.5 or 5 mg/kg of body weight), 5% difloxacin (2.5 or 5 mg/kg), enrofloxacin (5 mg/kg), or saline (0.9% NaCl) solution (control group), once daily for 5 days, and clinical signs were scored daily. On day 15, calves were euthanatized, and the percentage of diseased lung tissue was calculated. Swab specimens of the lungs were submitted for bacterial culture. RESULTS: Mortality rate and percentage of diseased lung tissue were significantly higher and cure rate and average daily gain were significantly lower for control calves, compared with calves in the treatment groups; however, no significant differences were found among treatment groups. Mannheimia haemolytica was isolated from the lungs of 10 control calves and from at least 2 calves in each of the treatment groups. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that difloxacin and enrofloxacin were equally effective for treatment of calves with experimentally induced pneumonic pasteurellosis. However, treatment of infected calves with difloxacin or enrofloxacin may not eliminate the organism.


Subject(s)
Anti-Infective Agents/therapeutic use , Cattle Diseases/drug therapy , Ciprofloxacin/analogs & derivatives , Fluoroquinolones , Mannheimia haemolytica/drug effects , Pasteurella Infections/veterinary , Animals , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/standards , Body Temperature , Cattle , Cattle Diseases/microbiology , Ciprofloxacin/administration & dosage , Ciprofloxacin/standards , Ciprofloxacin/therapeutic use , Enrofloxacin , Lung/microbiology , Lung/pathology , Male , Mannheimia haemolytica/growth & development , Pasteurella Infections/drug therapy , Quinolones/administration & dosage , Quinolones/standards , Quinolones/therapeutic use , Random Allocation , Weight Gain
SELECTION OF CITATIONS
SEARCH DETAIL
...